FDA (CBER)
GUIDANCE FINAL
Recommendations for Assessment of Blood Donor Eligibility, Donor Deferral and Blood Product Management in Response to Ebola Virus: Guidance for Industry
Published: 6/29/2026Detected: 6/29/2026
Summary preview
Provides FDA CBER recommendations for evaluating blood donor eligibility and deferring potentially exposed donors in response to Ebola virus, along with guidance for managing blood products to reduce…
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accountsafety
infectious_disease
#CBER
#blood donor eligibility
#donor deferral
#blood product management
#Ebola virus
Official Source Document Source Verified
Access the original document directly from FDA CBER.
More from FDA (CBER)
- Recommendations for Reducing the Risk of Transfusion-Transmitted Hepatitis B Virus: Guidance for Industry11/3/2026
- Guidance for Industry: Potency Assurance for Cellular and Gene Therapy Products11/2/2026
- Individualized Human Genome Editing Products: Considerations for BLA Submission and Postapproval Management10/27/2026
- Compliance Policy Regarding Blood and Blood Component Donation Suitability, Donor Eligibility and Source Plasma Quarantine Hold Requirements: Guidance for Industry10/14/2026
- Blood Pressure and Pulse Donor Eligibility Requirements – Compliance Policy: Guidance for Industry10/14/2026